DEPOT VERSUS ORAL NALTREXONE IN PAROLEES

$0P60FY2002DANIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 37167008 Paper 31318231 Paper 30663401 Paper 29949234 Paper 29172122 Paper 27667970 Paper 27168932 Paper 26922659 Paper 26320827 Paper 26214544 Paper 25762748 Paper 25460679 Paper 25058503 Paper 24525300 Paper 24359476 Paper 24353044 Paper 24333843 Paper 24201053 Paper 24186078 Paper 24126707 Paper 24073097 Paper 23916324 Paper 23827259 Paper 23810644 Paper 23612435 Paper 23566366 Paper 23551805 Paper 23454283 Paper 23428205 Paper 23223834 Paper 23188041 Paper 23061530 Paper 22981242 Paper 22795689 Paper 22747521 Paper 22694982 Paper 22513380 Paper 22472784 Paper 22445273 Paper 22443215 Paper 22302433 Paper 22011682 Paper 22001156 Paper 21968931 Paper 21925806 Paper 21790903 Paper 21679264 Paper 21668756 Paper 21625378 Paper 21508626 Paper 21477226 Paper 21333466 Paper 21314752 Paper 21306596 Paper 21299752 Paper 21232612 Paper 21199958 Paper 21112155 Paper 21045597 Paper 21036510 Paper 20889546 Paper 20673549 Paper 20640954 Paper 20640538 Paper 20093928 Paper 20053909 Paper 19914298 Paper 19783106 Paper 19725114 Paper 19503018 Paper 19429035 Paper 19398283 Paper 19345510 Paper 19339141 Paper 19219669 Paper 19062202 Paper 19034737 Paper 18704100 Paper 18704099 Paper 18674871 Paper 18650328 Paper 18625251 Paper 18594026 Paper 18572320 Paper 18540910 Paper 18508207 Paper 18321180 Paper 18288093 Paper 18231593 Paper 18227835 Paper 18216208 Paper 18182254 Paper 18079068 Paper 18056224 Paper 17982574 Paper 17664051 Paper 17632217 Paper 17398041 Paper 17375140 Paper 17164823

Abstract

DESCRIPTION: (provided by applicant) This project builds on an ongoing funded study (OS) which compares in nonblinded fashion 100 randomly assigned parolees given psychosocial treatment (PT) and 100 randomly assigned to PT plus oral naltrexone for six months. The proposed study (PS) adds a third group of 120 randomly assigned parolees who will be treated with PT plus depot naltrexone as well as 40 additional parolees treated with PT plus oral naltrexone. The effectiveness of depot naltrexone has never been studied in parolees. All participants will be evaluated at baseline, while in treatment, and at 6- and 12-month outcome evaluations. The primary study outcomes will compare 260 subjects (140 oral naltrexone, 120 depot) with regard to attendance/retention in treatment, urine toxicologies during treatment and at follow-up, re-incarcerations, arrests, and crimes during the one year of study participation, and psychosocial functioning over the study period. It is hypothesized that depot naltrexone will result in improved outcomes vis a vis oral naltrexone. The PS will also examine whether greater criminality/antisociality, psychopathology, gender, or current alcohol abuse problem are predictive of more negative outcomes.

View original record on NIH RePORTER →